If there's one lesson we can learn from Warren Buffet, it's the oracle's lifelong commitment to reading. “Read 500 pages like this every day,” Buffett once told a class of students. “That's how knowledge works. It builds up, like compound interest. All of you can do it, but I guarantee not many of you will do it.”
Despite decades of predictions to the contrary, the boring old 60/40 portfolio of US stocks and bonds refuses to die. That has not stopped the investment industry from trying to replace it, though, usually with something more complex, expensive, and suited for yesterday's market environment. The total portfolio approach might be the rare exception.
Here are five charts to counter all the financial misinformation on the internet that could lead to poor investment outcomes that you will find useful and thought-provoking.
Who captures the value of AI inference when it becomes cheap? And why [chosen AI company/ies]? The company/ies that can answer this question will most likely be the one(s) who win in this race to profitability. We'll see who will capture the value of AI inference if/when it becomes cheap.
As some of the most lucrative drugs lose exclusivity in the next few years, pharmaceutical giants are increasingly shopping around for biotechs to add to their portfolios — and they are more than happy to pay a hefty premium for the right company.
The latest Doximity compensation report reveals a physician workforce under mounting pressure. While average pay increased 3.7% from 2023 to 2024, this modest bump tells only part of the story.
Since September, 16 major drug companies have inked deals with the administration to lower prices. But in January — the time of year when pharmaceutical companies typically roll out price hikes — all 16 companies released higher list prices for some of their drugs.
South Carolina on Friday reported 124 new measles cases in the last three days, bringing the total number to 558 in the state's fast-growing outbreak. Cases have nearly doubled in the last week alone.
Five-year cancer survival rates in the US topped 70% for the first time, the American Cancer Society's annual report found. That means that a person diagnosed with cancer is 70% as likely to be alive five years later as the average person. It represents steady progress: In the 1970s, the figure was 50%.
High-profile studies reporting the presence of microplastics throughout the human body have been thrown into doubt by scientists who say the discoveries are probably the result of contamination and false positives. One chemist called the concerns “a bombshell.”
Durable goods data shows that there is a capex boom underway in the US economy, and the One Big Beautiful Bill is going to boost business fixed investment further over the coming quarters.
US manufacturing ended 2025 with a thud, capping a rough year for the sector. To recap, manufacturers shed 63,000 jobs, according to the latest data from the Bureau of Labor Statistics.
Interest rates have begun to come down. Inflation has mostly subsided, and the real economy is still doing decently well. So why are American consumers more pessimistic than they were during the depths of the Great Recession or the inflation of the late 1970s?
Thinking of accepting a new job? Here's a short list of questions that help you judge whether a job you're considering is going to crush your soul or not.
New Year's resolutions are cute, but have you tried reflecting on your mortality? Here's why it can help you have your best year yet.
I'll be honest—the past few years in real estate have been brutal for most investors.
Rising interest rates crushed valuations. Deals that penciled in 2021 became underwater by 2023. Many physicians I know put their real estate plans on hold, waiting for “better conditions.”
Here's what I've learned: the best conditions rarely feel comfortable in real time.
Right now, something fascinating is happening. Valuations have corrected 20-30%. New construction is plummeting—industrial completions down 59%, apartment deliveries expected to drop 34%. Yet occupancy remains at 93-95%.
Translation: prices are down, supply is falling, but demand is holding firm.
This is what institutional investors call a “recovery phase”—that golden window after a correction but before the crowd returns. Historically, this is where generational wealth gets built.
The problem? Most physicians lack access to institutional-quality deals.
That's why I'm hosting a webinar with Jonathan Spitz from Lightstone Direct—a 39-year operator managing $12+ billion with a 27.5% average IRR since 2004. What caught my attention: they invest 20% of their own capital in every deal, four times the industry average.
We're covering their 2026 playbook: where they're deploying capital, why workforce housing and shallow bay industrial, and how physicians can access these opportunities. We'll walk through live portfolio performance and actual deal structures with real project returns.
Whether you're actively investing in syndications or exploring alternatives to an overvalued stock market, this session delivers clarity on what's working now.
The recovery phase won't last forever. Institutional capital is returning, and the entry window is measured in quarters, not years.
[Register for this free webinar here and secure your spot →]
I hope to see you there.
—Jorge Sanchez, MD
